SNG Stock Overview
Synairgen plc discovers and develops drugs for respiratory diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Synairgen plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.025 |
| 52 Week High | UK£0.10 |
| 52 Week Low | UK£0.02 |
| Beta | -2.3 |
| 1 Month Change | -45.90% |
| 3 Month Change | -38.07% |
| 1 Year Change | -62.07% |
| 3 Year Change | -98.80% |
| 5 Year Change | -57.36% |
| Change since IPO | -98.39% |
Recent News & Updates
Recent updates
Here's Why We're Not Too Worried About Synairgen's (LON:SNG) Cash Burn Situation
Dec 09
Here's Why We're Watching Synairgen's (LON:SNG) Cash Burn Situation
Aug 24Is Synairgen (LON:SNG) In A Good Position To Invest In Growth?
Apr 29Companies Like Synairgen (LON:SNG) Could Be Quite Risky
Dec 27We're A Little Worried About Synairgen's (LON:SNG) Cash Burn Rate
Sep 13Companies Like Synairgen (LON:SNG) Could Be Quite Risky
May 31Here's Why We're Not Too Worried About Synairgen's (LON:SNG) Cash Burn Situation
Feb 06We're Hopeful That Synairgen (LON:SNG) Will Use Its Cash Wisely
Oct 21We're Hopeful That Synairgen (LON:SNG) Will Use Its Cash Wisely
Mar 29How Much Of Synairgen plc (LON:SNG) Do Institutions Own?
Dec 14Shareholder Returns
| SNG | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -42.8% | -5.1% | -2.2% |
| 1Y | -62.1% | -24.5% | 2.4% |
Return vs Industry: SNG underperformed the UK Biotechs industry which returned -24.5% over the past year.
Return vs Market: SNG underperformed the UK Market which returned 2.4% over the past year.
Price Volatility
| SNG volatility | |
|---|---|
| SNG Average Weekly Movement | 18.6% |
| Biotechs Industry Average Movement | 7.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.5% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: SNG's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: SNG's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 36 | Richard Marsden | www.synairgen.com |
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of severe viral lung infections that is in pre- clinical trial; and inhaled interferon beta IFN-ß, a naturally occurring protein that helps regulate the immune system to fight viruses, including coronaviruses. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.
Synairgen plc Fundamentals Summary
| SNG fundamental statistics | |
|---|---|
| Market cap | UK£5.08m |
| Earnings (TTM) | -UK£6.92m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.7x
P/E RatioIs SNG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SNG income statement (TTM) | |
|---|---|
| Revenue | UK£0 |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£0 |
| Other Expenses | UK£6.92m |
| Earnings | -UK£6.92m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.034 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did SNG perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 22:52 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Synairgen plc is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Cavendish |
| Mark Brewer | Cavendish |
| Paul Cuddon | Numis Securities Ltd. |